EyePoint, Inc.

EYPT

EyePoint, Inc.

EYPT

Insider Sentiment (TTM):

Last Purchase:2026-03-16Last Sale:2026-04-17Shares Purchased (TTM):1,500Shares Sold (TTM):122,378

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:88,329,746Shares Outstanding:85,999,000Institutional Ownership Pct.:102.71%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	110	78	102	75	71	85	100	80	91	271	281	133
Marketable Securities Current	70	145	204	129	185	233	271	174	189	28	50	3
Accounts And Other Receivables Net Current	0	1	1	1	1	0	1	0	1	3	1	0
Prepaid Expense And Other Assets Current	6	25	20	9	6	6	9	12	10	11	9	9
Inventory Net	2	1	2	2	3	2	2	3	4	4	4	5
Assets Current	189	250	329	216	265	327	383	269	295	318	345	150
Property Plant And Equipment Net	10	9	9	9	9	8	8	8	7	7	5	4
Operating Lease Right Of Use Asset	20	20	20	21	21	22	21	21	22	5	5	5
Restricted Cash And Cash Equivalents Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	9	9	6	6	6	6	6	2	-	-	0	-
Assets	228	288	364	252	301	363	418	301	324	329	355	160
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	17	19	10	10	20	16	12	7	14	7	7	10
Accrued Liabilities Current	22	16	24	18	11	18	18	14	13	16	18	13
Deferred Revenue Current	-	-	0	-	0	5	18	26	33	38	39	40
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	0	0
Other Liabilities Current	3	2	2	2	2	2	1	1	1	1	1	1
Liabilities Current	42	37	37	30	33	42	49	49	62	63	63	64
Long Term Debt Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Deferred Revenue Noncurrent	-	-	0	0	0	0	11	11	12	12	21	32
Operating Lease Liability Noncurrent	20	20	21	21	22	22	22	22	22	5	5	5
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	-	-	0	0
Liabilities	62	58	58	52	55	64	82	82	96	79	89	101
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,450	1,419	1,410	1,237	1,223	1,216	1,208	1,049	1,030	1,020	1,008	786
Retained Earnings Accumulated Deficit	-1,284	-1,190	-1,105	-1,037	-978	-918	-873	-832	-802	-771	-742	-728
Accumulated Other Comprehensive Income Loss Net Of…	1	1	1	1	1	1	1	1	1	1	1	1
Stockholders Equity	166	230	306	200	246	298	337	219	228	250	266	59
Liabilities And Stockholders Equity	228	288	364	252	301	363	418	301	324	329	355	160
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	85	83	83	70	69	69	68	54	52	50	49	35
Shares Outstanding	85	83	83	70	69	69	68	54	52	50	49	35

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	1.27%	1.86%	-9.10%	-	-	-	-	-	-	-	-	-
2025	18.69%	58.03%	71.80%	14.90%	38.03%	18.97%	33.84%	65.07%	37.00%	-20.69%	-12.63%	-17.96%
2024	-15.47%	-31.33%	-23.36%	-2.29%	-12.88%	3.71%	-23.64%	-37.88%	-26.40%	-14.52%	-6.60%	-16.72%
2023	-	-	-	-	-	-	-20.77%	191.35%	188.00%	-15.29%	-31.35%	-54.26%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.50	6.66	8.88	7.18	8.00	7.85	7.81	5.50	4.75	5.08	5.45	2.35
Quick Ratio	4.30	5.97	8.28	6.81	7.73	7.65	7.57	5.21	4.53	4.83	5.25	2.14
Working Capital	146.87M	212.04M	291.63M	186.01M	232.08M	285.31M	334.26M	219.76M	232.83M	255.13M	281.54M	86.27M
Leverage & Debt
Debt to Equity	0.37	0.25	0.19	0.26	0.22	0.22	0.24	0.38	0.42	0.32	0.33	1.73
Interest Coverage TTM	-	-	-	-	-	-	-	-	-	-199.62	-60.20	-50.52
Debt Ratio	0.27	0.20	0.16	0.20	0.18	0.18	0.20	0.27	0.30	0.24	0.25	0.63
Efficiency & Turnover
Asset Turnover TTM	0.01	0.02	0.08	0.15	0.17	0.16	0.11	0.20	0.20	0.21	0.17	0.22
Per Share Metrics
Diluted EPS TTM	-3.54	-3.16	-3.17	-2.93	-2.51	-2.10	-2.32	-1.90	-1.63	-1.49	-1.82	-2.61
Free Cash Flow Per Share TTM	-3.13	-3.16	-3.32	-3.04	-2.77	-2.17	-2.31	-2.17	-1.77	-0.31	-0.04	0.24
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-	93.29%
Operating Profit Margin TTM	-11,369.30%	-3,701.38%	-775.98%	-515.65%	-364.27%	-287.94%	-337.06%	-255.88%	-195.71%	-173.60%	-163.13%	-240.93%
Net Profit Margin TTM	-10,998.67%	-3,567.10%	-739.42%	-485.95%	-337.93%	-261.91%	-302.43%	-226.57%	-172.29%	-157.77%	-153.84%	-235.51%
Growth Metrics
Net Revenue Growth (1Y)	-94.63%	-86.41%	-27.50%	-7.38%	2.99%	12.04%	-5.97%	7.50%	34.98%	25.70%	11.14%	0.25%
Net Income Growth (1Y)	74.84%	85.04%	77.25%	98.66%	102.00%	86.00%	84.86%	3.42%	-18.06%	-22.97%	-30.77%	28.01%
EPS Growth (1Y)	41.27%	50.11%	36.22%	54.16%	53.70%	41.07%	27.74%	-27.18%	-42.13%	-45.43%	-33.59%	24.66%
Valuation Metrics
P/E TTM	-4.04	-4.08	-5.77	-4.86	-3.75	-2.58	-3.20	-4.20	-5.33	-13.86	-12.70	-3.06
P/B TTM	7.44	4.81	4.37	4.99	2.67	1.27	1.25	1.99	2.03	4.38	3.38	5.23
P/S TTM	443.89	145.59	42.66	23.60	12.68	6.75	9.69	9.52	9.19	21.87	19.54	7.20
Market Cap	1.24B	1.11B	1.34B	999.19M	658.00M	378.14M	419.42M	435.05M	462.89M	1.09B	899.07M	306.34M
Enterprise Value	1.13B	1.03B	1.24B	924.47M	586.71M	292.83M	319.57M	355.07M	371.97M	822.55M	617.66M	173.16M
Calculated Values
Free Cash Flow TTM	-271.28M	-271.54M	-243.39M	-213.59M	-194.04M	-151.31M	-130.28M	-118.04M	-94.36M	-16.65M	-1.61M	9.21M
Net Debt	-110.61M	-77.71M	-101.97M	-74.73M	-71.29M	-85.31M	-99.85M	-79.98M	-90.92M	-271.16M	-281.41M	-133.19M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-17Sale

Owner: Ribeiro, Ramiro

Title: Chief Medical Officer

Shares: 2,437

Price/Share: $15.00

Value: $36,555.00

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-03-16Purchase

Owner: Duker, Jay S.

Title: President and CEO

Shares: 1,500

Price/Share: $13.15

Value: $19,725.00

Shares Owned: 100,665

Relationship: Director,Officer

Ownership: Indirect

2026-03-04Sale

Owner: Ribeiro, Ramiro

Title: Chief Medical Officer

Shares: 2,438

Price/Share: $17.87

Value: $43,567.06

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-02-17Sale

Owner: Ribeiro, Ramiro

Title: Chief Medical Officer

Shares: 2,437

Price/Share: $15.00

Value: $36,555.00

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-01-05Sale

Owner: Ribeiro, Ramiro

Title: Chief Medical Officer

Shares: 42,544

Price/Share: $17.10

Value: $727,502.40

Shares Owned: -

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-17	Ribeiro, Ramiro	Officer	Chief Medical Officer	Direct	Sale	2,437	15.00	$36,555.00	0	4
2026-03-16	Duker, Jay S.	Director,Officer	President and CEO	Indirect	Purchase	1,500	13.15	$19,725.00	100,665	4
2026-03-04	Ribeiro, Ramiro	Officer	Chief Medical Officer	Direct	Sale	2,438	17.87	$43,567.06	0	4
2026-02-17	Ribeiro, Ramiro	Officer	Chief Medical Officer	Direct	Sale	2,437	15.00	$36,555.00	0	4
2026-01-05	Ribeiro, Ramiro	Officer	Chief Medical Officer	Direct	Sale	42,544	17.10	$727,502.40	0	4
2025-12-04	Cormorant, Asset Manageme…	Other	-	Indirect	Sale	60,000	15.70	$942,000.00	8,265,000	4
2025-12-04	Lurker, Nancy	Director	-	Direct	Sale	9,300	15.11	$140,523.00	206,547	4
2025-11-28	Lurker, Nancy	Director	-	Direct	Sale	500	14.95	$7,475.00	215,847	4
2025-11-11	Ribeiro, Ramiro	Officer	Chief Medical Officer	Direct	Sale	2,722	11.61	$31,602.42	0	4
2025-05-19	Zaderej, Karen L.	Director	-	Direct	Purchase	5,000	5.99	$29,950.00	36,500	4
2025-05-15	Zaderej, Karen L.	Director	-	Direct	Purchase	5,000	5.47	$27,350.00	26,500	4
2024-08-21	Ando, Goran	Director	-	Direct	Purchase	5,000	7.95	$39,750.00	13,150	4
2024-08-20	Dicicco, Wendy F	Director	-	Direct	Purchase	2,567	7.79	$19,996.93	9,967	4
2024-08-19	Zaderej, Karen L.	Director	-	Direct	Purchase	12,500	7.98	$99,750.00	16,500	4
2024-08-16	Lurker, Nancy	Director	-	Direct	Purchase	3,173	7.88	$25,003.24	97,635	4
2024-07-12	Guyer, David R	Director	-	Direct	Sale	11,625	10.06	$116,947.50	1,850	4
2024-06-03	Guyer, David R	Director	-	Direct	Sale	11,625	10.30	$119,737.50	3,700	4
2024-05-14	Guyer, David R	Director	-	Direct	Sale	11,625	12.65	$147,056.25	5,550	4
2024-05-06	Cormorant, Asset Manageme…	TenPercentOwner	-	Indirect	Purchase	850,000	12.03	$10,225,500.00	8,325,000	4
2024-04-18	Cormorant, Global Healthc…	TenPercentOwner	-	Indirect	Purchase	581,765	18.26	$10,623,028.90	7,475,000	4
2024-02-02	Jones, David Scott	Officer	SVP & Chief Commercial Officer	Direct	Sale	209	28.49	$5,954.41	37,962	4
2024-01-26	Jones, David Scott	Officer	SVP & Chief Commercial Officer	Direct	Sale	26,017	25.36	$659,791.12	37,962	4
2024-01-26	Paggiarino, Dario A.	Officer	Chief Medical Officer	Direct	Sale	49,325	25.53	$1,259,267.25	36,505	4
2024-01-25	Paggiarino, Dario A.	Officer	Chief Medical Officer	Direct	Sale	600	25.00	$15,000.00	36,505	4
2024-01-24	Paggiarino, Dario A.	Officer	Chief Medical Officer	Direct	Sale	11,251	25.02	$281,500.02	36,505	4
2024-01-24	Lurker, Nancy	Director,Officer	Executive Vice Chair	Direct	Sale	29,956	24.98	$748,300.88	135,441	4
2024-01-24	Jones, David Scott	Officer	SVP & Chief Commercial Officer	Direct	Sale	11,300	25.01	$282,613.00	37,962	4
2024-01-23	Jones, David Scott	Officer	SVP & Chief Commercial Officer	Direct	Sale	900	25.00	$22,500.00	37,962	4
2024-01-11	Liu, Ye	Director	-	Indirect	Sale	1,910,500	19.45	$37,159,225.00	100,221	4
2024-01-11	Cormorant, Asset Manageme…	TenPercentOwner	-	Indirect	Purchase	750,000	19.75	$14,812,500.00	6,893,235	4
2024-01-11	Ocumension, Therapeutics	Director	-	Direct	Sale	1,910,500	19.45	$37,159,225.00	100,221	4
2024-01-08	Paggiarino, Dario A.	Officer	Chief Medical Officer	Direct	Sale	22,913	21.13	$484,151.69	36,505	4
2023-12-13	Paggiarino, Dario A.	Officer	Chief Medical Officer	Direct	Sale	1,458	20.00	$29,160.00	25,707	4
2023-12-08	Cormorant, Asset Manageme…	TenPercentOwner	-	Indirect	Purchase	588,235	17.00	$9,999,995.00	6,038,235	4
2023-12-06	Ocumension, Therapeutics	Director	-	Direct	Sale	266,242	18.41	$4,901,515.22	2,010,721	4
2023-12-06	Liu, Ye	Director	-	Indirect	Sale	266,242	18.41	$4,901,515.22	2,010,721	4
2023-12-04	Cormorant, Global Healthc…	TenPercentOwner	-	Indirect	Purchase	1,919,057	26.82	$51,469,108.74	5,450,000	4
2023-12-04	Paggiarino, Dario A.	Officer	Chief Medical Officer	Direct	Sale	30,625	22.00	$673,750.00	25,707	4
2023-12-04	Lurker, Nancy	Director,Officer	Executive Vice Chair	Direct	Sale	20,000	20.76	$415,200.00	170,559	4
2023-12-04	Pine, Michael Craig	Officer	Chief Corp Dev.&Strat. Officer	Direct	Sale	46,000	21.40	$984,400.00	4,343	4/A
2023-09-01	Ew, Healthcare Partners-A…	TenPercentOwner	-	Indirect	Sale	20,000	9.90	$198,000.00	3,490,921	4/A
2023-09-01	Ew, Healthcare Partners, …	TenPercentOwner	-	Indirect	Sale	20,000	9.90	$198,000.00	3,490,921	4
2023-08-31	Essex, Woodlands Ix, Llc,…	TenPercentOwner,Other	-	Indirect	Sale	78,495	10.60	$832,047.00	3,510,921	4
2023-08-29	Ew, Healthcare Partners, …	TenPercentOwner,Other	-	Indirect	Sale	87,854	11.15	$979,572.10	3,650,392	4
2023-08-25	Essex, Woodlands Ix, Llc,…	TenPercentOwner,Other	-	Indirect	Sale	84,656	10.77	$911,745.12	3,799,104	4/A
2023-08-25	Essex, Woodlands Ix, Llc,…	TenPercentOwner,Other	-	Indirect	Sale	84,656	10.93	$925,290.08	3,799,104	4
2023-08-23	Ew, Healthcare Partners-A…	TenPercentOwner,Other	-	Indirect	Sale	121,103	13.05	$1,580,394.15	4,023,040	4
2023-05-30	Liu, Ye	Director	-	Indirect	Sale	1	6.00	$6.00	3,010,721	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

102.71%

Inst. Shares: 88,329,746

Shares Outstanding: 85,999,000

2025-12-31

113.37%

Inst. Shares: 83,043,850

Shares Outstanding: 73,251,000

2025-09-30

98.57%

Inst. Shares: 69,163,419

Shares Outstanding: 70,168,000

2025-06-30

97.84%

Inst. Shares: 68,416,923

Shares Outstanding: 69,926,000

2025-03-31

103.95%

Inst. Shares: 72,519,391

Shares Outstanding: 69,767,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	88,329,746	85,999,000	102.71%
2025-12-31	83,043,850	73,251,000	113.37%
2025-09-30	69,163,419	70,168,000	98.57%
2025-06-30	68,416,923	69,926,000	97.84%
2025-03-31	72,519,391	69,767,000	103.95%
2024-12-31	71,461,041	56,298,000	126.93%
2024-09-30	54,362,144	54,449,000	99.84%
2024-06-30	53,396,063	53,206,000	100.36%
2024-03-31	50,079,002	52,913,000	94.64%
2023-12-31	44,815,473	38,904,000	115.20%
2023-09-30	32,154,377	38,341,000	83.86%
2023-06-30	31,496,529	37,576,000	83.82%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

EyePoint, Inc. (EYPT) — SEC Financial Statements & Analysis

EyePoint, Inc. (EYPT) is a laboratory analytical instruments company, incorporated in DE. EyePoint, Inc. trades on Nasdaq as: EYPT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), EyePoint, Inc. reported a -94.63% year-over-year revenue growth, a Gross Profit Margin of 93.29% (TTM), a Debt-to-Equity ratio of 0.37x, a Price-to-Sales (P/S) ratio of 443.89x (TTM), a Price-to-Book (P/B) ratio of 7.44x (TTM), at a market cap of $1.24B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -94.63%
Gross Profit Margin TTM: 93.29%
Debt To Equity: 0.37x
P/S TTM: 443.89x
P/B TTM: 7.44x
Market Cap: $1.24B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is EyePoint, Inc. in?

EyePoint, Inc. (EYPT) operates in the Laboratory Analytical Instruments industry.

What is EYPT's market cap?

EyePoint, Inc. (EYPT) has a market capitalization of $1.24B as of 2026-06-30.

What exchange does EYPT trade on?

EyePoint, Inc. (EYPT) trades on the Nasdaq.

Where is EyePoint, Inc. incorporated?

EyePoint, Inc. is incorporated in DE.

EyePoint, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

EyePoint, Inc. (EYPT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Laboratory Analytical Instruments

Wall Street's data.
Main Street's price.

EyePoint, Inc. (EYPT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Laboratory Analytical Instruments

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.